The 340B rebate fight escalates: 20 key developments
For more than a year, major drugmakers have been pushing to replace the 340B program’s longstanding upfront discount structure with post-sale rebate models. Becker's Hospital Review
For more than a year, major drugmakers have been pushing to replace the 340B program’s longstanding upfront discount structure with post-sale rebate models. Becker's Hospital Review